Pyxis Oncology (NASDAQ:PYXS) Announces Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Pyxis Oncology (NASDAQ:PYXS) released its quarterly earnings results on Thursday. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.06), Zacks reports.

Pyxis Oncology Trading Down 5.3%

Pyxis Oncology stock traded down $0.17 during midday trading on Thursday, hitting $3.01. The stock had a trading volume of 1,264,919 shares, compared to its average volume of 1,623,279. The business has a fifty day moving average price of $2.53 and a 200 day moving average price of $1.96. Pyxis Oncology has a 12 month low of $1.03 and a 12 month high of $5.55. The stock has a market cap of $190.68 million, a P/E ratio of -2.30 and a beta of 1.31.

Analysts Set New Price Targets

A number of analysts have recently issued reports on PYXS shares. Wall Street Zen lowered shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings lowered shares of Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Wells Fargo & Company began coverage on shares of Pyxis Oncology in a research note on Monday, August 3rd. They set an “overweight” rating and a $12.00 price target on the stock. Leerink Partners cut their price objective on shares of Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating on the stock in a report on Thursday, July 2nd. Finally, Wedbush began coverage on shares of Pyxis Oncology in a research report on Tuesday, May 5th. They issued an “outperform” rating and a $6.00 price objective for the company. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Pyxis Oncology currently has a consensus rating of “Moderate Buy” and an average target price of $7.50.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in PYXS. Bank of America Corp DE raised its position in shares of Pyxis Oncology by 20.3% during the 4th quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock worth $84,000 after purchasing an additional 9,062 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Pyxis Oncology by 37.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 50,066 shares of the company’s stock valued at $58,000 after acquiring an additional 13,550 shares during the period. Vanguard Group Inc. grew its position in shares of Pyxis Oncology by 0.7% during the third quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock worth $4,804,000 after acquiring an additional 14,566 shares during the last quarter. Velan Capital Investment Management LP grew its position in shares of Pyxis Oncology by 37.5% during the third quarter. Velan Capital Investment Management LP now owns 55,000 shares of the company’s stock worth $122,000 after acquiring an additional 15,000 shares during the last quarter. Finally, LPL Financial LLC increased its holdings in shares of Pyxis Oncology by 150.7% in the 4th quarter. LPL Financial LLC now owns 35,102 shares of the company’s stock worth $40,000 after acquiring an additional 21,100 shares during the period. Institutional investors and hedge funds own 39.07% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.